Isothiocyanatostilbenes as novel c-Met inhibitors

Alana L. Gray1,2, David T. Coleman1,2, Reneau F. Castore1,2, Mohamed M. Mohyeldin3, Khalid A. El Sayed3, James A. Cardelli1,2

1Louisiana State University Health Sciences Center - Shreveport, Shreveport, LA, USA
2Feist-Weiller Cancer Center, Shreveport, LA, USA
3University of Louisiana - Monroe, Monroe, LA, USA

Correspondence to:
James A. Cardelli, e-mail: jcarde@lsuhsc.edu

Keywords: c-Met, isothiocyanatostilbenes, DIDS, H2DIDS

Received: August 05, 2015 Accepted: September 17, 2015 Published: October 31, 2015

ABSTRACT

The hepatocyte growth factor receptor (HGFR or c-Met) is a driver of multiple cancer subtypes. While there are several c-Met inhibitors in development, few have been approved for clinical use, warranting the need for continued research and development of c-Met targeting therapeutic modalities. The research presented here demonstrates a particular class of compounds known as isothiocyanatostilbenes can act as c-Met inhibitors in multiple cancer cell lines. Specifically, we found that 4,4′-Diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS) and 4,4′-Diisothiocyanatodihydrostilbene-2,2′-disulfonic acid (H2DIDS) had c-Met inhibitory effective doses in the low micromolar range while 4-acetamido-4′-isothiocyanatostilbene-2,2′-disulfonic acid (SITS) and 4,4′-dinitrostilbene-2,2′-disulfonic acid (DNDS) exhibited IC50s 100 to 1000 fold higher. These compounds displayed much greater selectivity for inhibiting c-Met activation compared to similar receptor tyrosine kinases. In addition, DIDS and H2DIDS reduced hepatocyte growth factor (HGF)-induced, but not epidermal growth factor (EGF)-induced, cell scattering, wound healing, and 3-dimensional (3D) proliferation of tumor cell spheroids. In-cell and cell-free assays suggested that DIDS and H2DIDS can inhibit and reverse c-Met phosphorylation, similar to SU11274. Additional data demonstrated that DIDS is tolerable in vivo. These data provide preliminary support for future studies examining DIDS, H2DIDS, and derivatives as potential c-Met therapeutics.

INTRODUCTION

The c-Met receptor tyrosine kinase has been demonstrated to be sufficient for oncogenic transformation [1], is a major regulator of invasive growth [2], and is a key contributor to tumor progression [3–5]. Therefore, it is not surprising that c-Met is an established therapeutic target for multiple types of cancers [reviewed in [6]]. Studies have shown that targeting the c-Met pathway can prevent and, in some cases, even reverse advanced stages of tumor progression as evidenced by a reduction in the number and size of metastatic lesions [7]. While several tyrosine kinase inhibitors (TKIs) have been identified as highly effective anti-cancer therapies, they are often prohibitively toxic and it is also common for patients to develop an acquired resistance to these drugs [8, 9]. Because of this, there is a continued need for the development of an expanded repertoire of TKI inhibitors.

A recent search of http://ClinicalTrials.gov revealed over 50 ongoing studies examining the role of c-Met in cancer. However, current FDA-approved c-Met inhibitors include only crizotinib (Xalkori; Pfizer) and cabozantinib (Cometriq; Exelixis). Both of these compounds are non-specific c-Met inhibitors, such that crizotinib also targets ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) and anaplastic lymphoma kinase (ALK) while cabozantinib inhibits vascular endothelial growth factor receptor 2 (VEGFR2), in addition to c-Met.

The c-Met pathway has been shown to be involved in normal homeostatic functions. However, dysregulation of c-Met signaling caused by receptor mutation, c-Met or HGF overexpression, gene amplification, or transcriptional
upregulation can result in various pathological outcomes, including cancer [10–13]. Activation of the c-Met receptor classically occurs following binding of its only known ligand, hepatocyte growth factor (HGF) prior to c-Met dimerization. This dimerization triggers multiple autophosphorylation events of the cytoplasmic tail of c-Met that are required for propagation of downstream signaling leading to increased cell proliferation, motility, and tumor cell invasion and metastasis. Multiple approaches targeting aberrant signaling through the c-Met pathway have been employed including anti-HGF and anti-c-Met antibodies, HGF and c-Met competitive antagonists, and inhibitors of signaling molecules downstream of c-Met activation [reviewed in [12]]. Our research has uncovered a class of compounds known as isothiocyanatostilbenes that act as c-Met inhibitors. We believe these compounds could serve as templates for the development of structurally similar and more efficacious anti-c-Met therapeutic agents.

RESULTS

Isothiocyanatostilbenes reduce c-Met phosphorylation

While using DIDS as an inhibitor of anion exchangers [14, 15], by happenstance, we found it potently inhibited c-Met phosphorylation. Importantly, DIDS reduced activation of c-Met at concentrations that were too low to inhibit anion exchangers. This indicated that DIDS may act as a c-Met inhibitor independent of its ability to target anion transport. The ability of DIDS to inhibit c-Met activation at a reasonably low concentration suggested DIDS and other stilbene analogs may be potential clinical therapeutics. We subsequently obtained additional stilbene compounds, H2DIDS, SITS, and DNDS, to assess their structure-activity relationship. These compounds have similar structural scaffolds and differ in the number of isothiocyanate substituent groups (Figure 1a). DNDS is structurally similar, but the two isothiocyanate substituents were replaced by nitro groups. Notably, H2DIDS only differs from DIDS by its reduced two-carbon linker chain that connects both aromatic rings; therefore, H2DIDS is the dihydro analog of DIDS. Western blot analysis of a serum-free dose response curve in DU145 prostate cancer epithelial cells showed that ~8 μM DIDS reduced c-Met activation and downstream Akt by ~90% (Figure 1b). Figures 1c–1e show that H2DIDS, SITS and DNDS inhibited c-Met by ~90% at 8 μM, 250 μM and 8 mM, respectively. These compounds also exhibited similar, though not identical, effective doses in PC3 prostate cancer (Figure S1a), MDA-MB-231 breast cancer (Figure S1b), and HCC1806 breast cancer (Figure S1c) cells. In all tested cell lines, DIDS and H2DIDS consistently demonstrated higher potencies for inhibiting c-Met activation by HGF; therefore, we focused on these two compounds for the remaining duration of the study. We found that DIDS and H2DIDS had slightly higher effective concentrations in dose response assays containing 10% FBS (Figure S2a and S2b).

To begin to assess the specificity of DIDS and H2DIDS, we treated DU145 cells with concentrations of DIDS and H2DIDS known to inhibit c-Met activation in combination with HGF, epidermal growth factor (EGF), or insulin-like growth factor (IGF). Western blot analysis revealed that concentrations of DIDS and H2DIDS that reduce c-Met activation do not significantly reduce EGFR or IGFRI activation (Figure 2a–2c), suggesting some degree of selectivity for c-Met.

DIDS and H2DIDS reduce HGF-induced cell motility and invasion

We next sought to determine the effect of these compounds on HGF-mediated phenotypes. DU145 cells exhibit a striking scattered and motile phenotype in response to EGF and HGF stimulation indicative of an epithelial-mesenchymal transition. An initial dose response scattering assay revealed that DIDS inhibited HGF-induced scattering between 1.8 μM and 8 μM and H2DIDS was effective between 8 μM and 40 μM (Figure S3). Using concentrations of DIDS and H2DIDS within this range, we discovered that these same concentrations were able to reduce HGF-induced, but not EGF-induced cell scattering (Figure 3a). This was consistent with our observations that DIDS and H2DIDS do not inhibit EGFR signaling (Figure 2b). Similarly, HGF-induced wound healing, a unique collective form of cell motility, was also significantly reduced while the same concentrations had minimal effects on EGF-mediated wound healing (Figure 3b–3d). We further examined dose response effects of DIDS and H2DIDS on c-Met phenotypes. Figure 4a and 4b show that DIDS and H2DIDS reduce HGF-induced wound healing in a dose response manner.

Similarly, these compounds inhibited HGF-induced invasion through Matrigel in a dose-dependent manner (Figure 4c and 4d). Although seemingly effective, the highest concentration of H2DIDS is not shown in Figure 4d due to a consistent but anomalous precipitant or interaction of H2DIDS with the Matrigel that resulted in grainy images precluding accurate quantitative analysis. DIDS was able to inhibit wound healing more effectively than similar concentrations used to inhibit invasion. H2DIDS appeared to be slightly more effective than DIDS in wound healing and much more effective in invasion assays. Notably, these concentrations of DIDS and H2DIDS had minimal effects on serum-free proliferation (Figure S4a and S4b) and proliferation in complete media (Figure S4c and S4d) in a 2D assay. Collectively, these data suggest that DIDS and H2DIDS can negatively affect c-Met/HGF-induced cell motility and invasion, but not by affecting proliferation in 2D.
DIDS and H2DIDS decrease HGF-induced 3D spheroid proliferation

In an attempt to better determine effective concentrations that may be useful for in vivo applications, we analyzed the effects of these stilbenes on cells grown in a 3D environment. For this assay, cells were embedded in Matrigel and treated concomitantly with DIDS or H2DIDS. Dose response curves showed that 5 μM DIDS and H2DIDS decreased HGF-induced DU145 spheroid growth by ~60% and still had some inhibitory effects as low as 40 nM (Figure 5a and 5b). These data suggest that DIDS and H2DIDS are effective in environments that more closely mimic in vivo conditions.

DIDS and H2DIDS inhibit and reverse c-Met phosphorylation

We next sought to better determine the mechanism by which isothiocyanato stilbenes inhibit c-Met phosphorylation. SU11274 is a well-established class I c-Met inhibitor that competitively binds the ATP-binding site of c-Met [16, 17]. In order to determine if DIDS acts in a manner similar to a class I c-Met inhibitor, we compared DIDS and H2DIDS to SU11274 in the following assays. First, ex vivo kinase assays were performed. At 500 nM, SU11274 reduced c-Met phosphorylation by ~70% and DIDS was found to reduce activation of wild-type c-Met with an IC₅₀ of 300 nM (Figure 6a). H2DIDS was not as effective as DIDS as the IC₅₀ for H2DIDS was 3.6 μM (Figure 6b). We also tested the ability of DIDS to inhibit c-Met M1250T (M1268T), a known mutant form of the receptor found in several types of cancers that can increase kinase activity and alter substrate specificity [18]. Similar to SU11274 [19], DIDS inhibited this form of the receptor with an IC₅₀ of 370 nM (Figure 6a).

Although it appeared DIDS can act as an ATP-binding pocket inhibitor, we further examined other possible mechanistic avenues. H1993 lung cancer cells were treated with DIDS, H2DIDS, and SU11274 prior to western blot analysis. H1993 cells have...
Figure 2: DIDS and H2DIDS reduce activation of c-Met, but not EGFR or IGFR. DU145 cells were treated with 33 ng/ml HGF a, 100 ng/ml EGF b, or 100 ng/ml IGF c, for 20 minutes in the presence of 4 μM DIDS or 25 μM H2DIDS. Western blot was used to analyze the indicated proteins. Densitometry shows changes in pMet compared to HGF control normalized to 1.

Figure 3: DIDS and H2DIDS reduce HGF-induced but not EGF-induced cell scattering and wound healing. a. DU145 cells were treated with 33 ng/ml HGF or 100 ng/ml EGF overnight in the presence of 4 μM DIDS or 25 μM H2DIDS. Cells were fixed and stained for actin. Representative images are shown.

(Continued)
c-Met amplification such that they have high levels of pMet, even in the absence of HGF, due to constitutive c-Met dimerization and autophosphorylation [20, 21]. Interestingly, SU11274 ameliorated pMet levels in H1993 cells while DIDS and H2DIDS had much less significant effects (Figure 6c). These data suggested that DIDS and H2DIDS act in a similar manner to SU11274 in their ability to inhibit c-Met kinase activity; however, SU11274 is able to ameliorate c-Met activation occurring independent of ligand-receptor interaction while DIDS and H2DIDS are much less effective.

It has been reported in the literature that DIDS can exhibit covalent crosslinking properties [22, 23]. To determine if this could account for c-Met inhibition, we treated DU145 cells with DIDS followed by one wash step and up to 1 hour recovery time prior to activation with HGF. Even as early as 20 minutes post-wash, HGF was able to activate c-Met to non-DIDS treated levels (Figure 6d) suggesting DIDS does not irreversibly bind c-Met. Surprisingly, we found that DIDS treatment post HGF treatment reduced pMet levels suggesting that DIDS is able to reverse c-Met activation under certain conditions.
Figure 4: DIDS and H2DIDS reduce HGF-induced wound healing and invasion in a dose-dependent manner. DU145 cells were treated with the indicated concentrations of DIDS a, c, or H2DIDS.

(Continued)

(Figure 6e). This has also been observed with SU11274 previously [24] and is further supported by our data (Figure 6d).

**DIDS is well-tolerated in mice**

Since DIDS and H2DIDS were capable of inhibiting c-Met activation at relatively low concentrations and no previous in vivo data on these compounds has been reported to our knowledge, we performed a preliminary experiment in a mouse model of breast cancer to determine if DIDS could be tolerated in vivo. For ~2 weeks, mice were treated with 5 mg/kg DIDS delivered intraperitoneally. No obvious signs of toxicity were observed, so DIDS treatments were increased to 10 mg/kg for ~2 additional weeks. Figure 7a shows that no change in body weight was observed in DIDS-treated mice compared to mice treated with DMSO control. Tumors became palpable on day 14 and measurements taken via caliper showed DIDS began to reduce tumor size towards the end of the experiment (Figure 7b). Differences in overall tumor weight were evident following necropsy (Figure 7c).

**DISCUSSION**

The accumulation of information implicating c-Met as a major regulator of tumor progression has and continues to drive the search for effective c-Met inhibitors...
for over 30 years [25]. Here, we report the finding that isothiocyanatostilbenes are c-Met inhibitors. Notably, DIDS and H2DIDS have two isothiocyanate groups and were consistently more effective at c-Met inhibition than SITS, which has one isothiocyanate group while the other was replaced by an acetamido group, and DNDS, which has no isothiocyanate groups. Additionally, SITS was more effective at reducing c-Met phosphorylation than DNDS based on western blot analysis of multiple cancer cell lines (Figures 1 and S1). These data suggest that the isothiocyanate group is the principal bioactive moiety for c-Met inhibition.

Cell-free kinase assays suggested DIDS has a 300 nM IC\textsubscript{50} for c-Met kinase activity while H2DIDS has an IC\textsubscript{50} in the low micromolar range (Figure 3a and 3b). These data are supported by the findings of Bültmann and Starke initially implicating DIDS as an ATP-binding site inhibitor of the P\textsubscript{2X} purinoceptor [26]. The reported IC\textsubscript{50} of DIDS for the P\textsubscript{2X} purinoceptor is similar to the IC\textsubscript{50} for c-Met (Figure 3a). Additionally, DIDS and H2DIDS inhibited HGF-mediated phenotypes in various cell assays, but had minimal effects on EGF-mediated phenotypes (Figures 3, 4, 5). Finally, preliminary studies examining toxicity of DIDS in an animal model suggest DIDS is well-tolerated \textit{in vivo} and may be anti-tumorigenic, even in a tumor model not primarily driven by c-Met (Figure 7). We predict that future studies examining DIDS efficacy in a c-Met driven tumor model may show greater anti-tumorigenic efficacy. Thus, the data presented herein identify isothiocyanatostilbene analogs as novel c-Met inhibitory leads in multiple model systems.

\textbf{Figure 4: (Continued) b, d.} in the presence of 33 ng/ml HGF. For invasion (c, d) wounded cells were overlaid with Matrigel diluted 1:5 in serum-free media. Data are shown as mean ± S.E.M.; n = 3.
Isothiocyanatostilbenes are classically used as anion transport inhibitors [27–29], although other roles for these compounds have been reported. Specifically, DIDS has been demonstrated to inhibit protein translocation across the ER membrane [30] and inhibit matrix metalloproteinase release [31], both at concentrations of 400 μM and greater. At low micromolar concentrations, DIDS was found to prevent the interaction of human immunodeficiency virus type-1 (HIV-1) with CD4 T-cell receptors [32] and reduce activity of succinic dehydrogenase and F_{0}F_{1}-ATP synthase [33].

Specificity is desirable in the clinic to ensure predictability, and although others have shown DIDS can affect other targets, our results found DIDS to be tolerable in mice and selective for c-Met over other tested receptor tyrosine kinases. Furthermore, of the two FDA-approved c-Met inhibitors, cabozantinib is prescribed with c-Met as the intended primary target; whereas crizotinib is prescribed based on ALK expression status. This highlights the lack of specific c-Met inhibitors approved for use, and that it is likely c-Met inhibitors with additional targets will prove more successful than specific inhibitors. Multi-kinase inhibitors can be effective at preventing the acquisition of resistance pathways, and c-Met signaling as a resistance pathway is amply reported throughout the literature [34–38], making it an important secondary target for therapy as well.

Interestingly, DIDS is reported to target P_{2x}, P_{2y}, and P_{2z} receptors [26, 39–41] and recent large scale genetic screening data from Wilson et al. suggest that P_{2y} receptor signaling is one mechanism that contributes to resistance to ALK inhibitors, such as crizotinib [42]. Based on this information, it’s conceivable that combination therapy of crizotinib and DIDS may prevent P_{2y} ALK inhibitor resistance while enhancing c-Met inhibition [43, 44], thus targeting two potential resistance pathways following crizotinib treatment.

We acknowledge the limitations of these compounds having possible promiscuous reactivity under particular conditions and recognize that the compounds tested within this study are likely not ideal...
candidates for therapeutic use; however, they can serve as scaffold templates to achieve improved specificity and pharmacologic profiles. Overall, these data identify isothiocyanatostilbenes as effective inhibitors of c-Met phosphorylation that are tolerable in vivo, based on studies using DIDS. Future studies will test the efficacy of these compounds and structurally similar derivatives toward c-Met-driven animal tumor models.

**MATERIALS AND METHODS**

**Ethics statement**

Investigation has been conducted in accordance with the ethical standards and according to the Declaration of Helsinki and according to national and international guidelines and has been approved by the authors’ institutional review board.

**Cell culture**

DU145, PC3, H1993 and HCC1806 cells were maintained in RPMI 1640 (Cellgro; Manassas, VA) supplemented with 10% fetal bovine serum (FBS) (Gemini; West Sacramento, CA). MDA-MB-231 cells were maintained in DMEM (Cellgro) supplemented with 10% FBS. All cells were obtained from American Type Culture Collection and grown at 37°C in 5% CO₂.

**Materials**

The stilbene compounds 4,4’-Diisothiocyanatostilbene-2,2’-disulfonic acid (DIDS), 4-acetamido-4’-isothiocyanatostilbene-2,2’-disulfonic acid (SITS), 4,4’-dinitrostilbene-2,2’-disulfonic acid (DNDS) were purchased from Sigma-Aldrich (St. Louis, MO) and 4,4’-Diisothiocyanatodihydrostilbene-2,2’-disulfonic acid...
(H2DIDS) was purchased from Life Technologies (Grand Island, NY). SU11274 was purchased from EMD Millipore (Billerica, MA). Recombinant growth factors include: HGF (EMD Millipore), EGF (Sigma-Aldrich), and IGF (PeproTech; Rocky Hill, NJ).

**Western blot analysis**

Cells were grown to ~70% confluency prior to treatment. Cells were serum-starved in serum-free media for 30 minutes prior to treatment in complete media or serum-free media for the indicated times. Cell lysates were collected in Laemmli (125 mM Tris, 4% SDS, 0.01% bromophenol blue, 30% sucrose) containing 0.5% β-mercaptoethanol and boiled ~8 minutes. Primary antibodies include: phospho-c-Met (Y1234/1235), phospho-Akt (S473), pEGFR (S845), pIGF-IRβ (Y1135/1136) (Cell Signaling Technology; Beverly, MA); α-actin (Sigma-Aldrich), c-Met (C-28) (Life Technologies). Secondary antibodies include: horseradish peroxidase-conjugated anti-rabbit and anti-mouse (GE Healthcare; Pittsburgh, PA). ECL 2 was used for chemiluminescent detection (Thermo Scientific; Rockford, IL). Densitometry was calculated using ImageJ (NIH).

**Wound healing and invasion**

DU145 cells were grown to ~100% confluency prior to wounding with the IncuCyte™ WoundMaker™ (Essen Bioscience; Ann Arbor, MI) and washed once with complete media. For invasion, cells were covered with Matrigel diluted 1:5 in serum-free RPMI following wounding. Cells were treated with 4 μM DIDS or 25 μM H2DIDS with or without 33 ng/ml HGF or 100 ng/ml EGF for up to 4 days. Images were taken every 4 hours with the IncuCyte™ ZOOM imaging system (Essen Bioscience). Quadruplicate replicates were used in each experiment. Data are presented as percent wound density ± standard error of the mean (S.E.M.).

**Scattering assay**

DU145 cells were grown to ~50% confluency. Cells were treated overnight with 4 μM DIDS or 25 μM H2DIDS in the presence or absence of 33 ng/ml HGF or 100 ng/ml EGF. Cells were fixed with 4% paraformaldehyde and stained with Oregon Green 488 phalloidin (Invitrogen; Carlsbad, CA). Images were acquired on an Eclipse TE300 inverted microscope (Nikon; Tokyo, Japan) with NIS Elements version 4.13.04.
Phosphorylation inhibition assay

Z'-LYTE™ Kinase Assay-Tyr6 Peptide kit (Invitrogen) was used to assess the ability of tested compounds to inhibit c-Met phosphorylation. Briefly, 20 μl/well reactions were set up in 96-well plates containing kinase buffer, 200 μM ATP, 4 μM Z-LYTE™ Tyr6 Peptide substrate, 2500 ng/ml c-Met kinase and DIDS or H2DIDS at various concentrations. After 1 hour incubation at room temperature, 10 μl development solution containing site-specific protease was added to each well. Incubation was continued for 1 hour. The reaction was then stopped, and the fluorescent signal ratio of 445 nm (coumarin)/520 nm (fluorescein) was determined on a plate reader (BioTek FLx800™), which reflects the peptide substrate cleavage status and/or the kinase inhibitory activity in the reaction. Appropriate controls were conducted to ensure that

Figure 7: DIDS is not toxic and may reduce tumor progression in vivo. Mice were treated with 5 mg/kg DIDS or equivalent volume DMSO for 14 days, followed by 10 mg/kg DIDS for an additional 16 days. a. Body weight of treated mice was measured throughout the duration of the experiment. b. Caliper measurements were taken on the indicated days and average tumor volume was calculated. c. Tumors were harvested at the end of the experiment and weighed. Data are shown as mean ± S.E.M.; n = 1; *p < 0.05.
DIDS and H2DIDS did not interfere with the reaction or emit detectable fluorescence. The IC<sub>50</sub> value for each compound was calculated by nonlinear regression of log concentration versus % c-Met phosphorylation ± S.E.M., implemented in GraphPad Prism version 5.0 (GraphPad Software, CA, USA).

2D proliferation

Cells were seeded to ~30% confluency prior to treatment with DIDS or H2DIDS at 0.5 μM, 2 μM, 8 μM, 32 μM, or 64 μM for 24 hours, 48 hours, or 72 hours in complete or serum-free RPMI. A T0 timepoint was also measured. For each timepoint, cells were exposed to Cell Titer Blue reagent (Promega) for 1 hour at 37°C 5% CO<sub>2</sub>. Experiments were performed with quadruplicate replicates. Fluorescence was measured using a BioTek Synergy 4 plate reader with Gen5 software.

3D spheroid proliferation

Prior to seeding, cells were incubated with 2.5 ng/μl CellTracker Red (Life Technologies) in complete DMEM lacking Phenol Red for 5 minutes at room temperature then centrifuged at 1000 RPM for 5 minutes. Dyed cells were resuspended in complete DMEM lacking Phenol Red and containing 5% Matrigel before adding 5 μM, 10 μM, 20 μM, or 40 μM DIDS or H2DIDS +/- HGF. The mixture of cells, treatments, and Matrigel in complete media was seeded at 2000 cells/well in a 96 well plate. The plate was centrifuged at 1000 RPM for 3 minutes to collect the cells into the bottom of the plate. Spheroid growth was imaged for up to 80 hours and analyzed for average red object area using the IncuCyte™ ZOOM software. Data are shown as percent change in spheroid growth between T0 and 80 hours with HGF normalized to 100% change in growth. Images were captured by the IncuCyte™ ZOOM imaging system and representative 10X images are shown.

Xenograft studies

All animal experiments were approved by the Institutional Animal Care and Use Committee, University of Louisiana at Monroe, and were handled in strict accordance with good animal practice as defined by the NIH guidelines. Athymic nude mice (Foxn1<sup>nu/nu</sup>, 4–5 weeks, female) were purchased from Harlan (Indianapolis, IN). The mice had free access to standard pellet food and water. The animals were acclimated to animal house facility conditions at a temperature of 18–25°C, with a relative humidity of 55 to 65% and a 12 light/dark cycle, for one week prior to the experiments.

MDA-MB-231/GFP human breast cancer cells were cultured and resuspended in serum-free DMEM medium (20 μl). After anesthesia, cell suspensions (1 × 10<sup>6</sup> cells/20 μl) were inoculated subcutaneously into the second mammary gland fat pad just beneath the nipple of each animal to generate orthotopic breast tumors. At 48 h post-inoculation, the mice were randomly divided into two groups: i) the vehicle-treated control group (n = 5), ii) the DIDS-treated group (n = 5). Treatment (3X/week) started 5 days post-inoculation with intraperitoneal (i.p.) administered vehicle control (DMSO/saline) or 5 mg/kg DIDS. The dose of DIDS was increased to 10 mg/kg on day 19 post-inoculation. The mice were monitored by measuring tumor volume, body weight, and clinical observation. Tumor volume (V) was calculated by V = L/2 × W<sup>2</sup>, where L was the length and W was the width of tumors. The results are presented as average ± S.E.M. Differences among various treatment groups were determined by the analysis of variance (ANOVA) followed by Dunnett’s test using PASW statistics version 18. A difference of P < 0.05 was considered statistically significant as compared to the vehicle-treated control group.

ACKNOWLEDGMENTS AND GRANT SUPPORT

The authors would like thank Dr. Ana Maria Dragoi of LSUHSC-S for assistance with spheroid analysis.

Research reported in this publication was partly supported by the National Cancer Institute of the National Institutes of Health under Award Number R15CA167475 (KE).

CONFLICTS OF INTEREST

The authors have no relevant conflicts to disclose.

REFERENCES

1. Jeffers M, Rong S, Anver M, Vande Woude G. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastatic phenotype in C127 cells. Oncogene. 1996; 13:853–856.
2. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 2006; 6:637–645.
3. Furge KA, Kiewlich D, Le P, Vo MN, Faure M, Howlett AR, Lipson KE, Vande Woude GF, Webb CP. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci U S A. 2001; 98:10722–10727.
4. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM. HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer. Clin Cancer Res. 2009; 15:3740–3750.
5. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar CM, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18:883–891.

6. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol. 2014; 9:314–326.

7. Smith DC, Smith MR, Sweeney C, Elfyki AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira A, Lara PN Jr, Lin CC, Srinivas S, et al. Coboazantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013; 31:412–419.

8. Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014; 11:473–481.

9. Petti C, Picco G, Martelli ML, Trisolini E, Bucci E, Perera T, Isella C, Medico E. Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells. Oncotarget. 2015; 6:221–33.

10. Appleman LJ. MET Signaling Pathway: A Rational Target for Cancer Therapy. J Clin Oncol. 2011; 29:4837–4838.

11. Fontes Jardim DL, Melo Gagliato Dd, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, et al. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014; 5:1837–45.

12. Blumenschein GR, Mills GB, Gonzalez-Angulo AM. Targeting the Hepatocyte Growth Factor-cMET Axis in Cancer Therapy. J Clin Oncol. 2012; 30:3287–3296.

13. Boccaccio C, Comoglio PM. MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure. Curr Opin Cell Biol. 2014; 31:98–105.

14. Halestrap AP. The monocarboxylate transporter family-Structure and functional characterization. IUBMB Life. 2012; 64:1–9.

15. Poole RC, Halestrap AP. Transport of lactate and other monocarboxylates across mammalian plasma membranes. Am J Physiol. 1993; 264:C761–C782.

16. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinlan LA, Shirazian S, Liang C, Podar K, Christensen JG, Salgia R. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003; 63:5462–5469.

17. Wang X, Le P, Liang C, Chan J, Kiewlich D, Miller T, Harris D, Sun L, Rice A, Vasile S, Blake RA, Howlett AR, Patel N, McMahon G, Lipson KE. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther. 2003; 2:1085–1092.

18. Bardelli A, Longati P, Gramaglia D, Basilio C, Tamagnone L, Giordano S, Ballinari D, Michieli P, Comoglio PM. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc Natl Acad Sci U S A. 1998; 95:14379–14383.

19. Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene. 2004; 23:5387–5393.

20. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB, Pan B-S. Lung Cancer Cell Lines Harboring MET Gene Amplification Are Dependent on Met for Growth and Survival. Cancer Res. 2007; 67:2081–2088.

21. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshi J, Lee JC, Naoki K, Richards WG, Sugarbaker D, Chen F, Rubin MA, Jänne PA, Girard L, Minna J, et al. Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis. Cancer Res. 2005; 65:5561–5570.

22. Hua S, Inesi G. Lys515-Lys492 cross-linking by DIDS interferes with substrate utilization by the sarcoplasmic reticulum ATPase. Biophys J. 1997; 73:2149–2155.

23. Wilson MC, Meredith D, Bunnun C, Sessions RB, Halestrap AP. Studies on the DIDS-binding Site of Monocarboxylate Transporter 1 Suggest a Homology Model of the Open Conformation and a Plausible Translocation Cycle. J Biol Chem. 2009; 284:20011–20021.

24. Ménard L, Parker PJ, Kermorgant S. Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways. Nat Commun. 2014; 5:3907.

25. Furlan A, Kherrouche Z, Montagne R, Copin M-C, Tulasne D. Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside. Cancer Res. 2014; 74:6737–6744.

26. Böttmann R, Starke K. Blockade by 4, 4′-diisothiocyanatosulfene-2, 2′-disulphonate (DIDS) of P2X-purinoceptors in rat vas deferens. Br J Pharmacol. 1994; 112:690–694.

27. Cabantchik ZI, Greger R. Chemical probes for anion transporters of mammalian cell membranes. Am J Physiol. 1992; 262:C803–C827.

28. Hwang SM, Koo NY, Jin M, Davies AJ, Chun GS, Choi SY, Kim JS, Park K, Elsworth J, Small EJ, Harzstark AL, Shirazian S, Liang C, Howlett AR, Patel N, McMahon G, Lipson KE. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther. 2003; 2:1085–1092.
29. McConnell KR, Aronson PS. Effects of inhibitors on anion exchangers in rabbit renal brush border membrane vesicles. J Biol Chem. 1994; 269:21489–21494.

30. Jungnickel B, Rapoport TA. DIDS (4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid) inhibits an early step of protein translocation across the mammalian ER membrane. FEBS Letters. 1993; 329:268–272.

31. Pamenter ME, Ryu J, Hua ST, Perkins GA, Mendiola VL, Gu XQ, Ellisman MH, Haddad GG. DIDS prevents ischemic membrane degradation in cultured hippocampal neurons by inhibiting matrix metalloproteinase release. PLoS One. 2012; 7:e43995.

32. Cardin AD, Smith PL, Hyde L, Blankenship DT, Bowlin TL, Schroeder K, Stauderman KA, Taylor DL, Tyns AS. Stilbene disulfonic acids. CD4 antagonists that block human immunodeficiency virus type-1 growth at multiple stages of the virus life cycle. J Biol Chem. 1991; 266:13355–13363.

33. Bernardes CF, Meyer-Fernandes JR, Martins OB, Vercesi AE. Inhibition of succinic dehydrogenase and F0F1-ATP synthase by 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS). Z Naturforsch C. 1997; 52:799–806.

34. Liska D, Chen C-T, Bachleitner-Hofmann T, Christensen JG, Weiser MR. HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation. Clin Cancer Res. 2011; 17:472–482.

35. Corso S, Giordano S. Cell-Autonomous and Non-Cell-Autonomous Mechanisms of HGF/MET-Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective. Cancer Discov. 2013; 3:978–992.

36. De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, Gabriele P, Comoglio PM, Boccaccio C. Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer. J Natl Cancer Inst. 2011; 103:645–661.

37. Chang K, Karnad A, Zhao S, Freeman JW. Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets. Oncotarget. 2015; 6:3507–18.

38. Mariani M, McHugh M, Petrillo M, Sieber S, He S, Andreoli M, Wu Z, Fiedler P, Scambia G, Shahabi S, Ferlini C. HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer. Oncotarget. 2014; 5:4855–4867.

39. Soltoff SP, McMillian MK, Talamo BR, Cantley LC. Blockade of ATP binding site of P2 purinoceptors in rat parotid acinar cells by isothiocyanate compounds. Biochem Pharmacol. 1993; 45:1936–1940.

40. Maminishkis A, Jalickie S, Blaug SA, Rymer J, Yerxa BR, Peterson WM, Miller SS. The P2Y(2) receptor agonist INS37217 stimulates RPE fluid transport in vitro and retinal reattachment in rat. Invest Ophthalmol Vis Sci. 2002; 43:3555–3566.

41. Peterson WM, Meggyesy C, Yu K, Miller SS. Extracellular ATP Activates Calcium Signaling, Ion, and Fluid Transport in Retinal Pigment Epithelium. J Neurosci. 1997; 17:2324–2337.

42. Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, Corsello SM, Capelletti M, Calles A, Butaney M, Sharifnia T, Gabriel SB, Mesirov JP, Hahn WC, Engelman JA, Meyerson M, et al. A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer. Cancer Cell. 2015; 27:397–408.

43. Tanimoto A, Yamada T, Nanjo S, Takeuchi S, Ebi H, Kita K, Matsumoto K, Yano S. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget. 2014; 5:4920–4928.

44. Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. Clin Cancer Res. 2012; 18:3592–3602.